News Protagonist Therapeutics, Inc.

Stocks

PTGX

US74366E1029

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 16:00:00 2026-07-17 EDT			5-day change	1st Jan Change
140.91 ^USD	+6.73%		+7.22%	+61.34%

07-07	Truist Raises Price Target on Protagonist Therapeutics to $145 From $121, Keeps Buy Rating	MT
06-25	Protagonist Therapeutics Insider Sold Shares Worth $1,061,460, According to a Recent SEC Filing	MT

All News

Mentions Relevance

07-16	Protagonist Therapeutics Reports Granting of Inducement Awards	AQ
07-07	Truist Raises Price Target on Protagonist Therapeutics to $145 From $121, Keeps Buy Rating	MT
07-01	Protagonist Therapeutics Reports Granting of Inducement Awards	AQ
06-25	Protagonist Therapeutics Insider Sold Shares Worth $1,061,460, According to a Recent SEC Filing	MT
06-16	Protagonist Therapeutics Reports Granting of Inducement Awards	AQ
06-10	Protagonist Therapeutics, Inc. Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026, Jun-10-2026 09:20 AM
06-01	Protagonist Therapeutics to Present Phase 3 VERIFY and Long-Term Rusfertide Data at the 2026 European Hematology Association Congress	AQ
05-28	Protagonist Therapeutics to Participate in Two Investment Bank Conferences in June 2026	AQ
05-13	Protagonist Therapeutics Insider Sold Shares Worth $7,509,000, According to a Recent SEC Filing	MT
05-12	Protagonist Therapeutics Insider Sold Shares Worth $5,918,880, According to a Recent SEC Filing	MT
05-06	Wedbush Adjusts Price Target on Protagonist Therapeutics to $118 From $112, Maintains Outperform Rating	MT
05-06	Protagonist Therapeutics: Q1 Earnings Snapshot	AQ
05-05	Protagonist Therapeutics : Quarterly Report for Quarter Ending March 31, 2026 (Form 10-Q)	PU
05-05	Protagonist Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
05-05	Protagonist Reports First Quarter 2026 Financial Results and Provides Corporate Update	AQ
04-28	Protagonist Therapeutics Opts Out of Rusfertide US Profit-Sharing Arrangement With Takeda Pharmaceutical	MT
04-28	Protagonist Exercises Rusfertide U.S. Opt-Out Right Under Takeda Collaboration	AQ
04-16	Protagonist Therapeutics Reports Granting of Inducement Awards	AQ
04-15	Truist Raises Price Target on Protagonist Therapeutics to $121 From $110, Keeps Buy Rating	MT
03-30	Protagonist Therapeutics Insider Sold Shares Worth $2,520,000, According to a Recent SEC Filing	MT
03-30	Protagonist Therapeutics Insider Sold Shares Worth $2,581,504, According to a Recent SEC Filing	MT
03-28	Protagonist Announces Presentation of One-Year Phase 3 Data for ICOTYDE(TM) in Moderate-to-Severe Plaque Psoriasis at the 2026 American Academy of Dermatology (AAD) Annual Meeting	AQ
03-26	Protagonist Therapeutics Insider Sold Shares Worth $5,524,700, According to a Recent SEC Filing	MT
03-19	Protagonist's Oral Peptide Platform Validated With Icotyde Approval for Psoriasis, Wedbush Says	MT
03-19	Wedbush Raises Price Target on Protagonist Therapeutics to $112 From $100, Keeps Outperform Rating	MT